Areteia Therapeutics key facts
- Developer of an oral medication intended to treat eosinophilic asthma.
- Areteia Therapeutics’s last known valuation is $1.3B (Feb 2024).
- It has raised $425.0M across 2 recorded rounds; the latest was Early Stage VC (Series A1) ($425.0M) in Feb 2024.
- Notable investors include Viking Global Investors, GV, ARCH Venture Partners, Marshall Wace, Maverick Capital — 11 tracked in total.
- Areteia Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Feb 2025 ($360.0M sold to 16 investors).
- Status: Out of Business.
Who backs Areteia Therapeutics
11+- ·The complete investor list: 11 names
- ·Watch Areteia Therapeutics: the Monday email on marks, rounds and moves
Areteia Therapeutics funding rounds
2 roundsAreteia Therapeutics valuation
Areteia Therapeutics's last known valuation is $1.3 billion, from Feb 2024. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Areteia Therapeutics raised?
Areteia Therapeutics has raised $425 million across 2 recorded rounds since 2022. The largest was a $425 million Series A1 in Feb 2024.
Areteia Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently in Feb 2025 ($360 million sold to 16 investors).
Areteia Therapeutics investors
11 investors are on record for Areteia Therapeutics, including Viking Global Investors, GV, ARCH Venture Partners and Marshall Wace. By type, the record holds 3 venture capital firms, 2 hedge funds and 1 asset manager. The Series A1 in Feb 2024 drew 9 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Encoded Therapeutics ($1.8 billion), Formation Bio ($1.7 billion) and Neurona Therapeutics ($1.1 billion).
About Areteia Therapeutics
Developer of an oral medication intended to treat eosinophilic asthma. The company's platform is focused on developing an oral drug that inhibits eosinophil maturation, showing potential to reduce inflammation and alleviate symptoms of severe asthma, enabling asthma patients to manage their condition more effectively while offering a more accessible alternative to injectable therapies.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Chapel Hill, NC, United States
- Founded
- 2022
- Employees
- 35
- Website
- areteiatx.com/
- Ownership
- Out of Business
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Areteia Therapeutics’s last known valuation, Feb 2024. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.